Bayer: glyphosate shortages not expected outside the US after executive order
The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, adding the move would not lead to shortages in other countries.
Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?
Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awaited path toward ending years of litigation. Here's a look at whether it could deliver the legal certainty Bayer needs.
Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains?
Bayer (BAYRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bayer shares make this surprising move after $7.25 billion Roundup settlement accord
Bayer stock slumped on Wednesday as the German giant set a preliminary accord to cap litigation over its weedkiller Roundup.
Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anderson said on Tuesday.
Bayer to make $10.5 bln push to settle roundup cases, Bloomberg reports
Bayer is planning to announce a $10.5 billion settlement push to settle current and future cancer lawsuits over its Roundup weedkiller, Bloomberg reported on Tuesday, citing people familiar with the plan.
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You Looking for a Top Momentum Pick? Why Bayer Aktiengesellschaft (BAYRY) is a Great Choice
Does Bayer Aktiengesellschaft (BAYRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
